When an RSV vaccine became available for use during pregnancy, it offered a natural experiment between various countries to see how it compared to a one-time antibody injection ...

A major UK-led clinical trial has found that a treatment commonly used to help premature babies breathe offers no benefit for ...

RSV can cause severe infection of the lungs in infants and older adults, according to Mayo Clinic. Researchers say this antibody helps reduce lower respiratory infections that need medical attention.

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months.

The CDC's Advisory Committee on Immunization Practices (ACIP) has issued new vaccine recommendations affecting RSV and flu ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

The U.S. Food and Drug Administration has approved Merck's Enflonsia, a treatment to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants. The company said ...

A new national guideline provides evidence-based recommendations for diagnosing, treating, and preventing pediatric ...

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent threat to child health worldwide.